PLS web banner

Venner PneuX™ – A breakthrough in critical care medicine

Ventilator-Associated Pneumonia (VAP) is the leading nosocomial* cause of mortality in the Intensive Care Unit (ICU).1 The occurrence happens between 48 and 72 hours after endotracheal intubation of patients. As a result, mortality rates are 15-50% higher in patients with VAP.1,2

*originating in a hospital

Aspirating of contaminated secretions in the airway is one of the most common causes of VAP3 and this can be caused by the following:

  • Secretion accumulated above the EndoTracheal Tube (ETT) cuff2
  • Re-intubation2
  • Colonisation of the upper airway with nosocomial pathogens2
  • Inappropriate ETT cuff pressure2
  • Bacterial colonisation and biofilm formation inside the ETT lumen2

Venner PneuX™ ETT and Venner PneuX™ Tracheostomy Tube (TT) have many features to aid in preventing VAP.

  1. Its innovative design incorporates a low-volume, low-pressure cuff2 allowing the mucosal pressure on the airway to be maintained and monitored.4
  2. Multiple Subglottic Secretion Drainage (SSD) ports2 permit irrigation of the airway and suctioning secretions that form above the cuff.
  3. In the likelihood of mucosal blockage the multiple SSD ports increase the ability to suction from the remaining patent port.


3rd WHO Global Forum on Medical Devices Poster >>

Contact local UK Distributor >>

Service Request Form (Word doc) >>

Venner PneuX™ image gallery


  1. Williams D.W. et al. A comparison of in vitro biofilm formation on Portex and LoTrach** endotracheal tubes
  2. Doyle A. et al. BMC Research Notes, 2011; 4:92
  3. Metheny N.A. et al. Critical care medicine, 2006; 34(4)
  4. Nseir S. et al. ,2011; Am J Respir Crit Care Med, 2011; 184(9):1041-1047

** Venner PneuX™ tracheal tubes were formerly known as LoTrach™